FDA Reports Current Shortage of Sodium Bicarbonate Injection - Distributor Impact

The FDA's Drug Shortages Database currently lists sodium bicarbonate injection (8.4% and 4.2% concentrations) in active shortage status as of multiple manufacturer reports filed in early 2025. This shortage directly affects wholesale drug distributor inventory allocation protocols and requires immediate review of hospital supply contracts under DSCSA transaction documentation requirements.

Regulatory Context

Under 21 U.S.C. § 356c, manufacturers must notify FDA at least six months before a discontinuance or interruption in supply of medically necessary drugs. The current sodium bicarbonate injection shortage involves multiple manufacturers reporting supply disruptions to FDA's Drug Shortage Staff. Wholesale drug distributors subject to state licensure requirements and 21 CFR Part 203 must maintain transaction documentation for all sodium bicarbonate injection units distributed, regardless of allocation constraints.

The Drug Supply Chain Security Act (DSCSA) mandates that wholesale distributors provide transaction information, transaction history, and transaction statements for each product transfer. During shortage conditions, distributors cannot modify these documentation requirements even when implementing allocation protocols for affected customers.

Shortage Status and Manufacturing Impact

FDA's current shortage listing identifies sodium bicarbonate injection 8.4% (50 mEq/50 mL) and 4.2% (5 mEq/10 mL) prefilled syringes as unavailable from multiple manufacturers. Pfizer reported supply interruption for its 8.4% 50 mL prefilled syringe presentation. Amphastar Pharmaceuticals and Hikma Pharmaceuticals have indicated limited availability across various sodium bicarbonate concentrations.

The shortage stems from manufacturing delays and increased demand. Sodium bicarbonate injection is used for metabolic acidosis treatment, cardiac arrest resuscitation, and contrast-induced nephropathy prevention. FDA classifies this as a medically necessary drug under 21 U.S.C. § 356c(a)(1), triggering mandatory shortage reporting obligations for manufacturers.

As of the most recent FDA Drug Shortages Database update, the estimated resolution timeframe varies by manufacturer. Pfizer has not provided a specific restoration date. Amphastar anticipates intermittent availability through Q2 2025. These timelines remain subject to change based on manufacturing capacity restoration.

Distributor Allocation and Compliance Requirements

Wholesale drug distributors implementing allocation protocols for sodium bicarbonate injection must document allocation methodologies for state board of pharmacy review. State pharmacy boards in 43 jurisdictions require wholesale distributors to maintain records demonstrating equitable distribution practices during shortage conditions. Allocation based on historical ordering patterns generally satisfies regulatory scrutiny, provided documentation substantiates the methodology.

Distributors cannot selectively fulfill orders to maximize margin during shortage periods. State wholesale drug distributor licensing statutes prohibit predatory pricing and preferential allocation without documented justification. California Business and Professions Code § 4169 and similar statutes in other states require distributors to demonstrate that allocation decisions serve public health interests rather than commercial advantage.

The DSCSA transaction documentation burden increases during shortages. Distributors must generate transaction information (TI), transaction history (TH), and transaction statements (TS) for every sodium bicarbonate injection unit transferred, regardless of whether the transfer is part of a partial allocation or full order fulfillment. Manual workarounds for allocation management cannot bypass DSCSA documentation requirements.

Hospital pharmacies relying on single-source distributor relationships for sodium bicarbonate injection face supply continuity risk. Distributors holding state licenses in multiple jurisdictions may redirect inventory to higher-volume customers or contractually obligated facilities. Hospitals without documented allocation agreements may experience delayed fulfillment or order cancellations during shortage periods.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold verified FDA registration — a baseline requirement for distributing sodium bicarbonate injection under 21 CFR Part 207. During shortage conditions, hospital procurement teams should prioritize distributors with documented compliance across multiple regulatory dimensions, not just FDA registration status.

The average compliance score in the ColdChainCheck directory is 51/100, placing the typical distributor in the "Fair" tier. This reflects adequate baseline licensure but limited verification of advanced compliance signals like NABP accreditation or clean enforcement records. Only 63 entities hold current NABP accreditation (formerly VAWD), representing 4.9% of tracked distributors. NABP-accredited distributors undergo additional operational audits beyond state licensure requirements, including verification of storage and handling protocols relevant to sodium bicarbonate injection temperature stability requirements (store at 20-25°C per USP).

Among tracked entities, 73 have at least one FDA recall, warning letter, or state enforcement action on record. During shortage periods, distributors with enforcement histories may face additional scrutiny from state boards of pharmacy if allocation practices appear inconsistent with documented corrective actions. The compliance score breakdown shows 28 entities in the "Excellent" tier (76-100 points), 281 in "Good" (61-75 points), 919 in "Fair" (26-60 points), 38 in "Poor" (11-25 points), and 9 in "Minimal" (0-10 points).

Practical Steps for Procurement and QA Teams

• Cross-reference current distributors against FDA registration status — Use the ColdChainCheck directory to verify that distributors supplying sodium bicarbonate injection hold active FDA establishment registration. Filter by state licensure to identify backup distributors in your jurisdiction.
• Review allocation documentation from primary distributors — Request written allocation protocols for sodium bicarbonate injection. Compare distributor compliance scores to assess regulatory risk. Distributors scoring below 40/100 may lack documentation infrastructure to support defensible allocation decisions during state board audits.
• Identify NABP-accredited alternatives — The 63 NABP-accredited entities in the directory represent distributors with verified operational controls. During shortages, these entities may provide more reliable allocation transparency due to accreditation audit requirements.
• Document due diligence for secondary sourcing — If primary distributors cannot fulfill orders, document the compliance verification process for secondary sources. ColdChainCheck entity pages provide license status, enforcement history, and last-updated dates for each data point.

ColdChainCheck monitors FDA drug shortage announcements and distributor enforcement actions as part of ongoing directory maintenance. See the compliance guides section for related coverage of DSCSA transaction documentation requirements and state wholesale drug distributor licensing obligations.

Disclaimer: This article provides informational content based on publicly available FDA data and regulatory requirements. It does not constitute legal or compliance advice. Verify all distributor compliance status with the relevant state board of pharmacy and FDA databases before making procurement decisions.